Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year increase in earnings on higher revenues when it ...

Vertex Pharmaceuticals boasts a strong cystic fibrosis franchise along with exciting new products and pipeline candidates.

Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance. Where Is Vertex Pharmaceuticals Standing Right Now?

A single Journavx pill costs around $15 without insurance, according to Vertex Pharmaceuticals, the drug's manufacturer. Journavx's FDA approval was based on studies of patients right after surgery.

The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Vertex Pharmaceuticals scored a major win with the EU approval of ALYFTREK, expanding its cystic fibrosis treatment access in Europe. This regulatory greenlight paves the way for stronger market ...

Vertex Pharmaceuticals secured EU approval for ALYFTREK, a next-gen cystic fibrosis therapy boasting a better efficacy profile and broader eligibility. The drug outperformed KAFTRIO in reducing sweat ...

Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment The success of Vertex’s opioid alternative Journavx could aid a group of biotechs that aim to take a similar ...